InvestorsHub Logo
Followers 8
Posts 273
Boards Moderated 0
Alias Born 03/22/2013

Re: jessellivermore post# 168851

Tuesday, 12/25/2018 11:23:00 AM

Tuesday, December 25, 2018 11:23:00 AM

Post# of 426487
Funny, on the one hand you trash and marginalize drug reps, at the same time you place JT/Amarin on this intellectual pedestal, wondering how they are going to accomplish GIA with 400 of these worthless, dysfunctional, bordering on criminal, dispensing of information "drug reps". WTF?
Big pharma, biotechs, pretty much every single scientific entity with a product to sell, relies on and spends SIGNIFICANT $$$ hiring, training, and providing for their sales force. Why do you think the Market is hammering Amarin. One reason is because the ONLY have 400 sales reps, and why? For window dressing? Just performing their part for the Trump economy?
And BTW, Amarin provides reps with a list of clinicians to make at least 1-2 calls on per month, there is NO prospecting! 80% of their growth/business comes from 20% of their clients. That, my friend, is why they may often be visiting an office where the ENTIRE staff bought shares in Amarin (laughable). It's the nature of sales, repetition creates habits......and people/docs buy from people they like..... docs don't even know why they may suddenly think of writing a Vascepa Rx... maybe because one of those brain dead drug reps was in their office that morning.
While an MIT and Harvard education may create highly functional, front of brain thinking, you are still being sold, in ways you've never even dreamed of! Me, I've been in this stock for 7 years, it's been a daily, pride swallowing siege. The thought of holding this sh** for another 3-4 years makes me want to vomit. I'd gladly take $40+ per share and move on. Enough is enough. BO is much more of a reality than you know.

Webster
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News